2. Search Result
Search Result
Results for "

gastric mucosal ulcers

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

1

Fluorescent Dyes

1

Biochemical Assay Reagents

2

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0360
    Rebamipide
    5+ Cited Publications

    OPC12759; Proamipide

    		 COX Inflammation/Immunology Cancer
    Rebamipide (OPC12759) is an orally active gastroprotective agent that enhances the production of endogenous PGs (especially intragastric PGE2) by inducing COX-2 expression, thereby protecting the gastric mucosa from injury. Rebamipide exerts anti-proliferative activity against gastric cancer cells. Rebamipide can be used in studies of mucosal protection, gastroduodenal ulcer, gastritis and gastric cancer .
    Rebamipide
  • HY-B0327
    Irsogladine
    3 Publications Verification

    Dicloguamine

    		 Phosphodiesterase (PDE) NF-κB AP-1 TRP Channel Interleukin Related Inflammation/Immunology Cancer
    Irsogladine (Dicloguamine) is an orally active gastric mucosal protective agent. Irsogladine inhibits breast cancer recurrence and lung metastasis in nude mice . Irsogladine inhibits the transcriptional activities of NF-κB and AP-1, suppresses the activities of PDE and PDE4 to elevate intracellular cAMP levels, and activates TRPV1 and KATP channels. Irsogladine enhances iNOS expression, NO production, and the activation of cAMP-responsive elements. Irsogladine inhibits the development and progression of intestinal polyps in Apc-mutant mice. Irsogladine alleviates oxidative stress, increases gastric mucosal blood flow, and stimulates the production of endogenous prostaglandins. Irsogladine promotes insulin secretion in MIN6 cells. Irsogladine inhibits tumor angiogenesis, cancer cell proliferation, and the production of proinflammatory cytokines. Irsogladine exerts protective effects on astrocytes in ethanol/hydrochloric acid-induced gastric ulcers in mice. Irsogladine prevents colitis in IL-10 gene-deficient mice by reducing the production of IL-12 and IL-23. Irsogladine upregulates gap junction intercellular communication in pancreatic cancer cells via the PKA pathway. Irsogladine is applicable to research related to breast cancer, intestinal polyposis, gastric ulcer, spontaneous colitis, glioma, liver cancer, and pancreatic cancer [5][6] .
    Irsogladine
  • HY-165131
    Δ7-Avenasterol

    Delta-7-avenasterol

    		 Prostaglandin Receptor COX Inflammation/Immunology
    Δ7-Avenasterol (Delta-7-avenasterol) is a phytosterol that binds to prostaglandin E2 receptor (prostaglandin E2 receptor) and cyclooxygenase-2 (COX-2). Δ7-Avenasterol is applicable to research related to gastric ulcer, anti-inflammation and antioxidation .
    Δ7-Avenasterol
  • HY-122762
    Cetraxate hydrochloride

    DV-1006

    		 Ser/Thr Protease Inflammation/Immunology
    Cetraxate hydrochloride (DV-1006), an orally active anti-ulcer agent with mucosal protective effects, can be used for gastric ulcers research . Cetraxate hydrochloride is a potent acrosomal proteinase acrosin inhibitor with a Ki and an IC50 of 0.94 μM and 3.3 μM, respectively .
    Cetraxate hydrochloride
  • HY-120314
    GEA 3162

    		Apoptosis Caspase Endogenous Metabolite Inflammation/Immunology
    GEA 3162 is an orally active compound that acts as a NO/ONOO⁻ donor. GEA 3162 significantly inhibits the activation of human polymorphonuclear leukocytes (PMNs) through the cGMP pathway, inhibits the release of inflammatory mediators, and exerts anti-inflammatory and protective effects. GEA 3162 induces apoptosis of neutrophils and bone marrow cells by activating caspase-2/3/8/9 through the ONOO⁻ pathway. GEA 3162 has a bidirectional effect in the rat gastric ulcer model: at low doses, it significantly reduces gastric mucosal damage, while at high doses, it aggravates the ulcer area. GEA 3162 can be used for research on inflammatory conditions such as gastric ulcers .
    GEA 3162
  • HY-126941
    Hecogenin acetate

    		ERK MMP Reactive Oxygen Species (ROS) NF-κB p38 MAPK NOD-like Receptor (NLR) TRP Channel TNF Receptor Interleukin Related Infection Neurological Disease Inflammation/Immunology Endocrinology
    Hecogenin acetate is an orally active steroid saponin aglycone with extensive biological activities. Hecogenin acetate inhibits the phosphorylation of NF-κB and p38 MAPK signaling pathways, antagonizes TRPA1/TRPM8 channels, inhibits the production of pro-inflammatory cytokines, and has anti-inflammatory and analgesic effects. Hecogenin acetate inhibits the production of ROS and the activation of NLRP3 inflammasome; downregulates the expression of MMP-2, and has neuroprotective and anti-tumor activities. Hecogenin acetate enhances gastric mucosal defense and promotes ulcer healing. Hecogenin acetate can be used in combination with certain antibiotics to regulate bacterial efflux pumps and restore antibiotic sensitivity .
    Hecogenin acetate
  • HY-106054
    Nocloprost

    		Prostaglandin Receptor Metabolic Disease Inflammation/Immunology
    Nocloprost, a prostaglandin E2 (PGE2) analog, is an orally active EP1- and EP3-receptor agonist. Nocloprost inhibits evoked [ 3H]ACh release. Nocloprost has gastroprotective and ulcer-healing properties. Nocloprost accelerates the healing of chronic gastric ulcerations and enhances mucosal growth in rats .
    Nocloprost
  • HY-B0360R
    Rebamipide (Standard)

    		COX Reference Standards Inflammation/Immunology Cancer
    Rebamipide (Standard) is the analytical standard of Rebamipide. This product is intended for research and analytical applications. Rebamipide (OPC12759) is an orally active gastroprotective agent that enhances the production of endogenous PGs (especially intragastric PGE2) by inducing COX-2 expression, thereby protecting the gastric mucosa from injury. Rebamipide exerts anti-proliferative activity against gastric cancer cells. Rebamipide can be used in studies of mucosal protection, gastroduodenal ulcer, gastritis and gastric cancer .
    Rebamipide (Standard)
  • HY-117358
    KW-5805

    		Others Inflammation/Immunology
    KW-5805 is an anti-ulcer agent that promotes the biosynthesis, storage and secretion of gastric mucus, improves gastric mucosal hemodynamics, and inhibits the decrease in gastric mucosal blood volume and mucosal oxygenation caused by steroid shock .
    KW-5805
  • HY-119762
    Spizofurone

    AG-629

    		 Prostaglandin Receptor Cardiovascular Disease
    Spizofurone is an anti-ulcer compound with increased gastric mucosal blood flow activity and oral activity. Spizofurone has a similar mechanism of action to PGE2 (HY-101952), Spizofurone is capable of acting through local and systemic pathways and may promote ulcer healing by improving blood supply to the gastric mucosa. Spizofurone can be used to study the development strategy of gastric ulcer .
    Spizofurone
  • HY-106322
    IO-21

    		Bacterial Infection
    IO-21 (Compound 3) is a candidate cytoprotective agent. IO-21 exhibits a marked cytoprotective effect. IO-21 shows a potent inhibitory activity against HCl•ethanol-induced lesions. IO-21 shows a MIC of 50 μg/mL against Helicobacter pylori 7795. IO-21 can be used in the research of gastric mucosal ulcers .
    IO-21
  • HY-19153
    Nepaprazole

    rel-TY-11345 free base

    		 Proton Pump Inflammation/Immunology
    Nepaprazole (rel-TY-11345 free base) is a proton pump inhibitor. Nepaprazole inhibits H +/K +-ATPase activity in isolated rabbit gastric mucosal microsomes with the IC50 values of 5.8 μM and 9.9 μM at pH 6.0 and pH 7.4, respectively. Nepaprazole can be used for study of peptic ulcer diseases .
    Nepaprazole
  • HY-129424
    Mezolidon

    KM-1146

    		 Others Inflammation/Immunology
    Mezolidon (KM-1146) is a compound with anti-ulcer activity, which exerts its anti-ulcer activity by enhancing the defense ability of gastric mucosa, especially by increasing and maintaining gastric mucosal blood flow and protecting gastric mucosal potential difference. Mezolidon can be used for the study of gastric mucosal protection .
    Mezolidon
  • HY-165489
    AU-006

    		Endogenous Metabolite Inflammation/Immunology Endocrinology
    AU-006 is an orally active inhibitor of gastric acid secretion, with anti-ulcer effects. AU-006 does not rely on NO and mucus regulation. AU-006 significantly prevents 95% of gastric mucosal damage caused by ethanol and has broad-spectrum protective effects against chemical corrosive damage. AU-006 can be used for research on gastric ulcers .
    .
    AU-006
  • HY-120314A
    GEA 3162 hydrochloride

    		Apoptosis Caspase Endogenous Metabolite Inflammation/Immunology
    GEA 3162 hydrochloride is an orally active compound that acts as a NO/ONOO⁻ donor. GEA 3162 hydrochloride significantly inhibits the activation of human polymorphonuclear leukocytes (PMNs) through the cGMP pathway, inhibits the release of inflammatory mediators, and exerts anti-inflammatory and protective effects. GEA 3162 hydrochloride induces apoptosis of neutrophils and bone marrow cells by activating caspase-2/3/8/9 through the ONOO⁻ pathway. GEA 3162 hydrochloride has a bidirectional effect in the rat gastric ulcer model: at low doses, it significantly reduces gastric mucosal damage, while at high doses, it aggravates the ulcer area. GEA 3162 hydrochloride can be used for research on inflammatory conditions such as gastric ulcers .
    GEA 3162 hydrochloride
  • HY-B0377G
    Famotidine (GMP)

    MK-208 (GMP)

    		 Histamine Receptor Inflammation/Immunology Cancer
    Famotidine GMP (MK-208 GMP) is Famotidine (HY-B0377) produced in GMP guideline. Famotidine GMP is a competitive histamine H2-receptor antagonist, inhibits gastric secretion, activates the gastric mucosal defensive mechanisms. Famotidine GMP ameliorates peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD) in rats model .
    Famotidine (GMP)
  • HY-N15354
    Jujubasaponin IV

    		Others Others
    Jujubasaponin IV is a triterpenoid saponin compound found in Zizyphi Fructus. Animal studies have shown that Jujubasaponin IV possesses certain anti-ulcer activity, possibly through mechanisms such as enhancing the gastric mucosal barrier or inhibiting gastric acid secretion. Jujubasaponin IV can be used in research on digestive system diseases, particularly in the study of gastric ulcer mechanisms .
    Jujubasaponin IV
  • HY-W747307
    FCE 20700

    		Prostaglandin Receptor Inflammation/Immunology
    FCE 20700 is an orally active PGE2 analogue. FCE 20700 can prevent gastric mucosal damage and in inhibit gastric acid and pepsin secretion. FCE 20700 can be used for the research of gastrointestinal ulcer .
    FCE 20700
  • HY-182393
    IGN-2098

    		Histamine Receptor Inflammation/Immunology
    IGN-2098 is an orally active, competitive histamine H2 receptor antagonist with a pA2 value of 7.32. IGN-2098 inhibits basal and stimulated gastric acid secretion. IGN-2098 accelerates ulcer healing, suppresses ulcer edge elevation, and protects gastric and duodenal mucosa from damage. IGN-2098 can be used in research related to gastric ulcers .
    IGN-2098

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: